T-cell receptor and CD28 co-stimulatory pathway (TCR/CD28)

The T-cell receptor (TCR) and CD28 co-stimulatory pathway represent the fundamental "two-signal" model for T-lymphocyte activation (StatPearls, 2023). Signal 1 is mediated by the TCR complex upon recognition of an antigen-MHC complex, while Signal 2 is provided by the CD28 receptor interacting with B7 ligands (CD80/CD86) on antigen-presenting cells (PubMed, PMID: 23885281). Activation of this dual-signal axis triggers downstream cascades, including the PI3K/Akt/mTOR and PLC-gamma/calcineurin/NFAT pathways, which are essential for T-cell survival, proliferation, and cytokine secretion (UniProt, P16284). In clinical practice, this pathway is a major therapeutic target for managing autoimmune disorders and preventing organ transplant rejection through drugs like abatacept and calcineurin inhibitors (NIH, 2024). Furthermore, the manipulation of these signals is central to modern oncology, particularly in the design of chimeric antigen receptor (CAR) T-cells, which incorporate CD28 signaling domains to enhance anti-tumor activity (Nature Reviews Immunology, 2021). This signaling network also plays a critical role in the development of immune checkpoint inhibitors, which aim to overcome the inhibitory signals that often dampen this pathway in the tumor microenvironment.

Other names

T-cell activation pathwayTCR-CD28 signaling axisT-lymphocyte activation cascadeTwo-signal immune activation model

Drugs targeting this axis work by either blocking the primary signal (TCR/CD3 complex), inhibiting the essential co-stimulatory signal (CD28) by competing for B7 ligands, or suppressing downstream intracellular signaling mediators such as calcineurin or mTOR to prevent T-cell activation and proliferation.